Dark Horse Consulting Group Forms Strategic Partnerships to Accelerate Cell and Gene Therapy Development in China
核心洞察
Dark Horse Consulting Group (搜索) has signed two strategic MOUs to provide comprehensive pathways for cell and gene therapy development in China's rapidly growing advanced therapy market.
The partnership with KunTuo Medical Research combines DHCG's global regulatory expertise with KunTuo's clinical research capabilities across Chinese institutions.
A separate collaboration with Porton Advanced (搜索) creates a streamlined pathway for Investigator-Initiated Trials, leveraging Porton's 24 IND clearances and end-to-end manufacturing infrastructure.
Dark Horse Consulting Group (搜索) (DHCG), a leader in strategic and operational biotherapeutics consulting, has announced two significant partnerships aimed at accelerating cell and gene therapy development in China, one of the most rapidly growing and strategically significant markets for advanced therapies.
Strategic Collaboration with KunTuo Medical Research
In May 2026, DHCG signed a Memorandum of Understanding with KunTuo Medical Research and Development (搜索) (Beijing) Co., Ltd., a full-service contract research organization dedicated to clinical research services in China. The collaboration unites DHCG's comprehensive regulatory, CMC, nonclinical, clinical, quality and compliance, supply chain, commercial launch, and business analytics consulting capabilities with KunTuo's deep clinical research expertise and abundant clinical resources across China.
KunTuo, established by IQVIA as a dedicated CRO for the Chinese market, maintains IQVIA's exceptional quality management system and has provided more than 1,000 clinical research services for pharmaceutical and medical device companies in China and abroad since its founding in 2011. The organization brings a dedicated cell and gene therapy clinical team with experience developing and managing complex clinical programs across leading Chinese research institutions.
"This MOU with KunTuo represents another meaningful expansion of the integrated solutions we can offer our client partners who are looking to advance their programs in China," said Anthony Davies, Ph.D., Founder and CEO of Dark Horse Consulting Group (搜索). "KunTuo's experience in cell and gene therapy clinical trials, combined with DHCG's global strategic consulting depth, creates a genuinely differentiated offering for developers at every stage of the development journey."
Partnership with Porton Advanced for Manufacturing Solutions
In April 2026, DHCG also established a strategic collaboration with Porton Advanced (搜索), a premier contract development and manufacturing organization specializing in Advanced Therapy Medicinal Products (ATMPs). This partnership focuses specifically on enabling Investigator-Initiated Trials (IITs) in China by combining DHCG's regulatory expertise with Porton Advanced's end-to-end GMP manufacturing infrastructure.
Porton Advanced (搜索)'s capabilities span lentiviral vectors (搜索), AAV (搜索), mRNA/LNP (搜索), plasmids, and engineered cell therapies including CAR-T (搜索), CAR-NK, and iPSC-derived products. The company holds 24 IND clearances across the NMPA and FDA and has successfully supported over 30 IITs to date. Their state-of-the-art, GMP-compliant facilities span 215,000 square feet, equipped with 10 viral vector GMP-compliant production lines, 12 cell therapy GMP-compliant production suites and multiple clean rooms.
"This MOU with Porton Advanced (搜索) represents a streamlined pathway for our client partners that are interested in undertaking an IIT in China," Davies explained. "For programs targeting the Chinese market, particularly those pursuing IITs, having a trusted, proven manufacturing partner with NMPA-aligned quality systems will provide DHCG clients with decreased times to first-in-human, and rapid tech transfer and manufacture."
Addressing Market Challenges
Both partnerships address a persistent challenge in the Chinese market: navigating the intersection of international regulatory strategy and local clinical operations. For clients seeking to conduct trials in China, these collaborations reduce the friction between global regulatory strategy and local clinical execution that can result in delays in trial initiation.
Andrew Chen, CEO of Porton Advanced (搜索), emphasized the complementary nature of the partnership: "As demand for IIT-enabling services in China from overseas sponsors continues to grow, the combination of Porton Advanced's end-to-end cell and gene therapy CDMO capabilities and proven track record, as well as DHCG's strategic consulting depth creates a genuinely differentiated offering for developers at every stage."
Comprehensive Service Integration
The partnerships enable sponsors and investigators to move their programs forward with greater speed, confidence, and efficiency. DHCG brings deep expertise in regulatory requirements governing trials in China, FDA expectations when evaluating data generated in Chinese clinical settings, and clinical design considerations necessary to ensure trial data can be effectively leveraged in future regulatory submissions.
As of now, Porton Advanced (搜索) has successfully supported clients to secure 24 global IND approvals from NMPA, FDA, and Medsafe, with 11 ongoing Phase I/II ATMP projects. The company has also supported the successful transition of several overseas clinical-stage pipelines into China, demonstrating the practical value of these integrated approaches to market entry.